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ABSTRACT
The Breast Cancer Group of the Japanese Radiation Oncology Study Group conducted a nationwide questionnaire survey
on the clinical practice of postoperative radiotherapy for breast-conserving treatment for breast cancer. This questionnaire
consisted of 18 questions pertaining to the annual number of treated patients, planning method, contouring structure, field
design, dose-fractionated regimen, application of hypofractionated radiotherapy, boost irradiation, radiotherapy for syn-
chronously bilateral breast cancer, and accelerated partial breast irradiation. The web-based questionnaire had responses
from 293 Japanese hospitals. The results indicated the following: treatment planning is performed using relatively similar
field designs and delivery methods; the field-in-field technique is used at more than one-third of institutes; the commonest
criteria for boost irradiation is based on the surgical margin width (≤5mm) and the second commonest criteria was age
(≤40 or ≤50 years), although some facilities applied a different age criterion (>70 years) for omitting a tumor bed boost;
for conventional fractionation, almost all institutes delivered 50Gy in 25 fractions to the conserved whole breast and
10Gy in 5 fractions to the tumor bed. This survey revealed that 43% of hospitals offered hypofractionated radiotherapy,
and the most common regimens were 42.56Gy in 16 fractions for whole-breast irradiation and 10.64Gy in 4 fractions for
boost irradiation. Almost all of the facilities irradiated both breasts simultaneously for synchronously bilateral breast cancer,
and accelerated partial breast irradiation was rarely offered in Japan. This survey provided an overview of the current clinical
practice of radiotherapy for breast-conserving treatment of breast cancer in Japan.
Keywords: nationwide questionnaire survey; Japanese clinical practice; postoperative radiotherapy; breast-
conserving treatment
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INTRODUCTION
For patients with early-stage breast cancer, radiotherapy to the conserved
breast after breast-conserving surgery (post-BCS RT) reduces the risk of
local recurrence and cancer-related death, with a potential survival bene-
fit [1, 2]. For these reasons, post-BCS RT has gained widespread use for
patients with early-stage breast cancer. Technological advances in radi-
ation therapy and a deeper understanding of clinicopathological features
of breast cancer have led to an increase in the variety of methods avail-
able for irradiating the conserved breast.
Currently, different options for radiotherapy are available for
breast-conserving treatment. An increase in dose delivery methods
has resulted from advanced techniques such as 3D conformal radio-
therapy (3DCRT), the field-in-field technique (FIF) and intensity-
modulated radiation therapy (IMRT). Some studies have shown that
boost irradiation (BI) to the tumor bed brings better local control,
especially in younger patients, although different clinical trials have
used different dose-fraction regimens [3, 4]. Such evidence may result
in the different adaptability and dose-fractionation regimens for BI
among different hospitals. Furthermore, hypofractionated radiation
schedules have been offered more frequently based on the high levels
of evidence for long-term safety and efficacy [5, 6]. A greater under-
standing of breast cancer biology would allow for optimizing the field
design for post-BCS RT. Several studies have reported that acceler-
ated partial breast irradiation (APBI) or partial breast irradiation
(PBI) provides satisfactory outcomes in some categories of early-
stage breast cancer [7, 8]. It is thus possible that, based on such
reports, diverse radiotherapy (dose–fraction regimens and targeted
volumes) may be prevalent in clinical practice.
After the American College of Surgeons Oncology Group
(ACOSOG) Z-0011 trial revealed the feasibility of milder surgical
axillary management for patients with low-volume axillary disease,
axillary dissection is being increasingly omitted in eligible patients
(one or two positive sentinel lymph nodes, having undergone breast
conservation, scheduled to receive postoperative radiotherapy and
systemic adjuvant therapy) [9]. This landmark trial has altered the
treatment paradigm for axillary management and has led to the rec-
ommendation to omit additional axillary surgery beyond sentinel
lymph node biopsy in women meeting the ACOSOG Z0011 inclu-
sion criteria by the National Comprehensive Cancer Network and
the American Society of Clinical Oncology [10, 11]. However, the
optimal radiation field for use in such patients with low-volume axil-
lary disease treated by mild axillary management is still unclear,
although a standard ‘tangent’ or a ‘high tangent’ is generally con-
sidered to be appropriate for axillary disease control. Such changes
may lead to differences in targeted volumes for post-BCS RT.
Elucidating the details of the variation among hospitals in Japan
may help improve medical practices and patient management, and
bring to light new obstacles that need to be addressed. This informa-
tion could also be used for future clinical trials and for helping to
inform national health insurance policy. To assess whether variations
exist in post-BCS RT practices among different Japanese institutions,
the Breast Cancer Group of the Japanese Radiation Oncology Study
Group (JROSG-BCG), with the support of the Japanese Society for
Radiation Oncology (JASTRO), conducted a nationwide question-
naire survey on the clinical practice of post-BCS RT in Japan. The
aim of this study was to report the results of the tendencies in the
clinical practice of post-BCS RT in Japan from the nationwide survey.
MATERIALS AND METHODS
The JASTRO approved and supported the initiative to conduct the
questionnaire survey. This survey was conducted with institutional eth-
ical approval. The JROSG-BCG formulated a web-based questionnaire
system and requested the participation of all Japanese institutes with
≥1 full-time radiation oncologist and with an annual record of treating
≥10 patients with post-BCS RT in clinical practice. Radiation oncolo-
gists were requested to answer 18 questions related to post-BCS RT in
six categories as follows (see Supplementary Data 1 for details of the
questionnaire): (i) the number of the patients treated annually (three
questions); (ii) the planning method/the contouring structure (six
questions); (iii) the field design (one question); (iv) the dose-
fractionated regimen/the practice of hypofractionated radiotherapy
(four questions); (v) the criteria for applying BI (two questions); and
(vi) the practice of bilateral post-BCS RT/APBI (two questions). Open
access to the questionnaire was available during April, May, July and
August of 2016, for a total of 4 months. For convenience, university
hospitals and hospitals designated for cancer treatment were termed
specialized hospitals (SHs) since they specialized in cancer treatment,
whereas the other hospitals were termed general hospitals (GHs).
RESULTS
Completed questionnaires were received from 293 institutes. According
to the statistical data of 2015 provided by the JASTRO Database
Committee, the collection rate of this survey accounted for 55% (293/
535) of the total number of institutes (535) that the JASTRO has
authorized as facilities specializing in radiotherapy with ≥1 full-time
radiation oncologist. Although 66% (192/293) of the institutes were
GHs, we obtained responses from 89% (101/113) of SHs.
Number of patients treated annually
Figure 1 shows the number and ratio of patients treated annually
with RT or post-BCS RT. In this study, 77% (225/293) of hospitals
conducted RT for ≤600 patients; 76% (224/293) of the included
facilities conducted post-BCS RT for ≤90 women.
Treatment planning/Contouring for treatment planning
Computed tomography (CT)-based 3DCRT was performed at 98%
(288/293) of the included hospitals. In 92% (271/293) of all hospi-
tals, treatment plans were calculated with inhomogeneity correction
and with the use of accurate and novel algorithms such as the super-
position algorithm. To make homogenous dose distributions, 57%
(167/293) of hospitals used physical or dynamic wedge filters and
39% (114/293) employed the FIF technique as the first approach
used commonly in each hospital (Fig. 2). The FIF technique was
the most commonly used alternative method to homogenize dose
distributions (36%, 106/293), if the first approach failed to do it.
Among the institutes where no alternative method was generally
employed, 47% (45/95) of them used the FIF technique as the first
approach. For contouring of the target and the organs at risk
(OARs), 66% (192/293) of all institutes formulated a contour of






/jrr/article-abstract/60/1/142/5195524 by Library,Faculty of Agriculture/G
raduate School of Agriculture,Kyoto U
niversity user on 21 June 2019
the converted breast for the clinical target volume (CTV), while
66% (192/293) and 76% (222/293) of all institutes delineated the
regions of interest such as the heart and the lung to evaluate the
dose distributions, respectively.
Field design of post-breast-conserving
surgery radiotherapy
The questionnaire contained questions about the most popular
landmarks selected to define the edges of a treatment field for post-
BCS RT in each hospital (see Supplementary data 2 for details of
the survey result, Figs S1–S6). The middle line was the most com-
mon medial edge of the field (71%, 209/293). For the lateral edge,
50% (146/293) applied the boundary from the middle axillary line
to posterior, though 4% (11/293) employed the more posterior
landmarks such as the posterior axillary line or the anterior aspect
of the ipsilateral latissimus. For the cranial edge, the sternal notch
was selected by 55% (162/293) of hospitals. For the caudal edge,
64% (188/293) of facilities used the line 1–2 cm below the infra-
mammary fold. The line ≥1 cm anterior to an ipsilateral nipple was
the most commonly selected anterior edge for 86% (251/293) of all
included institutions, while the posterior edges were based on the
central lung distance (CLD) in 69% (202/293) of hospitals; this
was the distance between the anterior edge of the lung and the mid-
point of the posterior field edge. For the posterior edge, 25% (73/
293) of institutes selected a CLD of <2 cm, 33% (96/293) selected
a CLD of <2.5 cm, and 11% (33/293) selected a CLD of <3 cm.
Dose and fractionation; criteria for hypofractionated
whole-breast irradiation
All participating facilities answered the question about the use of
conventional fractionated (CF) and hypofractionated (HF) regi-
mens, but we did not receive the detailed information on the HF
dose fractionation from two facilities. Table 1A shows the total
dose, dose per fraction, and the total fractions in CF post-BCS RT
(dose in fraction <2.5 Gy). With the exception of four institutes
that did not employ the CF regimen, 98% (284/289) of all hospitals
used a protocol of 50 Gy in 25 fractions for whole-breast irradiation
(WBI) and 92% (266/289) used a BI of 10 Gy in 5 fractions.
Table 1B describes the variety of doses and fractionations of HF
post-BCS RT (dose in fraction ≥2.5 Gy). Compared with CF regi-
mens, there was a wider dispersion in HF schedules among different
institutes, especially in those for the dose fractionations of BI. A
total of 38% (111/293) of the hospitals employed HF regimens for
WBI of 40–43.2 Gy in 16 fractions; the protocol of 42.56 Gy in 16
fractions was used in 30% (89/293) of hospitals and was the most
common of all HF regimens. Eleven hospitals did not provide BI in
HF schedules. In this study, 43% (127/293) of all hospitals con-
ducted HF post-BCS RT and 11% (33/293) of facilities performed
HF post-BCS RT more frequently in clinical practice than CF post-
BCS RT (Fig. 3). Regarding the eligibility criteria for HF post-BCS
RT, 40% (51/127) of the institutes employed the criteria recom-
mended by the Japanese Breast Cancer Society (JBCS) [12]. The
criteria included the following: (i) aged ≥50 years at diagnosis; (ii)
pathologic stage of T1–2 N0 and receipt of breast-conserving sur-
gery; (iii) no history of systemic chemotherapy; (iv) within the
breast, the minimum dose was ≥93% and the maximum dose was
≤107% of the prescription dose.
Criteria to apply boost irradiation
This survey asked the participating institutes to list the eligibility cri-
teria for offering BI to the tumor bed. All participating hospitals
answered the question regarding the eligibility criteria, but in the
analysis of surgical margin conditions, we used 89% (262/293) of
answers regarding the superficial margin close to the skin or the
deep margin close to the muscle and 95% (278/293) of answers
regarding the lateral (horizontal) margin, because these answers
were clear enough to analyze. Table 2 shows the factors of each
institute taken into consideration in determining whether to use BI
and the dominant factors that had a strong impact on the decision-
making process. Surgical margin was the most commonly used
determining factor. Overall, 97% (283/293) of hospitals considered
surgical margin as an important factor for decision-making, and 94%
(275/293) of the facilities regarded surgical margin as a dominant
factor, although the definition of surgical margin as a determining
Fig. 1. The percentage of hospitals categorized according to
the number of the patients treated annually. (a) The
percentage of hospitals categorized according to the total
number of patients treated with RT annually. (b) The
percentage of hospitals categorized according to the total
number of patients treated with post-BCS RT annually. (c).
The percentage of hospitals categorized according to the
ratio of the annual number of patients treated with post-
BCS RT to that of the annual number of patients treated
with RT. RT = radiation therapy; post-BCS RT =
radiotherapy after breast-conserving surgery.
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factor differed between the hospitals in this survey (Table 3). For
the criteria, some institutes used the margin width, whereas others
referred to the margin status (‘close’ or ‘positive’) on the histo-
logical reports. As for the lateral margin, 70% (194/278) of the hos-
pitals regarded a ≤5-mm margin width as a determinant for the
choice of BI. For the superficial margin close to the skin or the
deep margin close to the muscle, the most commonly used marginal
determinant for BI was also the ≤5-mm margin width (45%, 119/
262 or 43%, 113/262, respectively). Age was the second factor used
commonly in the decision about BI. In 38% (110/293) of facilities,
age was regarded as one of the deciding factors, and it was regarded
as a dominant factor in 19% (55/293) of hospitals. According to
the analysis of 97 answers reporting clear information on the thresh-
olds of age for BI, the common thresholds were ≤40 and ≤50 years
(36%, 35/97 and 52%, 50/97, respectively), but four facilities used
age >70 years as the age range for omitting BI (see Supplementary
data 2, Table S1).
Method for the bilateral post-BCS RT/practice of APBI
In patients with synchronously diagnosed bilateral breast cancers, 85%
(250/293) of all hospitals delivered the post-BCS WBI to the bilateral
conserved breast without any interval between irradiation to the right
and the left sides. A total of 7% (21/293) of the hospitals conducted
these procedures with an interval of a few weeks between procedures,
4% (13/293) of the facilities offered these procedures sequentially, and
the other institutes used their institutional procedures. Only 2% (5/
293) of the institutes offered APBI as part of clinical practice, and 1%
(3/293) offered this procedure as part of clinical trials. In this study,
97% (284/293) of all hospitals in Japan did not offer APBI.
DISCUSSION
As far as we know, this nationwide web-based questionnaire survey
is the first investigation to reveal the Japanese clinical practice of
post-BCS RT with an analysis of radiation planning. All of the 293
participating institutes responded, and the survey results contain the
opinions of the majority of the SHs (89%, 101/113). Therefore, the
results of this survey likely indicate the tendencies of current
Japanese clinical practice in post-BCS RT.
Almost all hospitals conducted post-BCS RT using 3DCRT planning
based on CT simulation with inhomogeneity correction and with rela-
tively novel calculation algorithms (e.g. superposition). There were no
major discrepancies in field designs between different institutions,
although some minor differences were noted. The contours of the con-
served breast, heart, and lung were delineated for precise dose delivery in
more than half of the included institutes. This survey revealed the popu-
larity of the FIF technique for achieving homogenous dose delivery. This
result might be a reflection of the prevalence of 3DCRT in Japan, which
might have helped increase awareness of the efficacy of the FIF technique
among clinicians. The importance of ensuring homogeneity of dose deliv-
ery to the conserved breast has been widely recognized and will likely
lead to a more widespread use of the FIF technique. Furthermore, the
updated guideline of an ASTRO, which recommended 3D conformal
treatment planning with the FIF technique, might promote the spread of
the FIF technique in Japan [6].
This investigation revealed the uniformity in the schedules of
CF post-BCS RT and the frequency of HF post-BCS RT use among
Japanese institutes. CF schedules in almost all institutes used 50 Gy
in 25 fractions (5 days per week) for WBI and 10 Gy in 5 fractions
for BI. HF schedules were more varied than those of CF and dif-
fered in total doses and dose fractionations. The most common
regimens were 42.56 Gy in 16 fractions (5 days per week) for WBI
and 10.64 Gy in 4 fractions for BI. Our results showed that 43% of
hospitals employed the HF regimen, and 11% offered the HF sched-
ule more frequently than they did the CF schedule. In the UK, the
HF regimen (40 Gy in 15 fractions) has been adopted widely based
on the long-term follow-up results of randomized controlled trials
[13]. Several studies have revealed the prevalence of the HF regi-
men in Canada and the USA [14, 15]. The HF regimen was not
used commonly in Japan compared with European countries such
as the UK or the Netherlands. One of the reasons might be that the
results of the JCOG 0906, a Japanese multicenter safety trial of HF
post-BCS RT [16], had not commenced at the start of this survey.
We speculate that the HF regimen has likely gained (and will gain
Fig. 2. The percentage of hospitals categorized according to
the methods employed to ensure homogeneity in dose
distribution. (a). Percentages of hospitals using the various
initial strategies as their most popular first choice for
achieving a homogeneous dose distribution. (b) Percentages
of hospitals using the various alternative strategies for
achieving a homogeneous dose distribution if the initial
strategy did not provide satisfactory homogeneity. (c)
Percentages of hospitals using the various initial strategies
as their most popular first choice for achieving a
homogeneous dose distribution, among hospitals that did
not use an alternative approach. WF = wedge filter; FIF =
field-in-field technique; IMRT = intensity-modulated
radiotherapy.
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more) popularity in Japan, based on the increased awareness of its
efficacy [17, 18], the future announcement of the JCOG0906 result,
and the ASTRO’s updated guideline, which contained more flexible
eligibility criteria for use of the HF regimen than the JBCS criteria
[6].
According to this survey, surgical margin was the most common
determining factor for selection of BI, and age was the second fac-
tor, although different criteria were adopted in different institutes.
Of the Japanese institutes in this survey, 98% considered surgical
margin as an important factor, and 94% regarded it as the dominant
factor to be used solely in determining the selection of BI. Many of
the facilities in this survey used the ≤5-mm margin width in deter-
mining the selection of BI. The EORTC 22881–10882 trial clearly
revealed the benefit of BI in terms of local control in patients with
microscopically complete excision of invasive disease, although BI
could lead to worse cosmetic outcomes or severe fibrosis without an
apparent impact on survival benefit [3, 4]. The Japanese tendency
to base the use of BI on margin width might be related to the
hypothesis that a narrower margin is associated with a risk of local
recurrence and the concern that BI could cause a worse cosmetic
outcome. However, the panel of the Society of Surgical Oncology
and ASTRO concluded that choosing BI should not be dependent
Table 1. The list of doses and fractionations for whole-breast irradiation and boost irradiation, and the percentages of
hospitals using this approach
Total dose (Gy) Does/Fr (Gy) Total Fr The number (%)
of all hospitals
The number (%) of
specialized hospitals
A. Conventional fractionation
WB 50 2 25 286 (98) 101 (100)
50.4 1.8 28 2 (0.7) 0 (0)
47.5 2.375 20 1 (0.3) 0 (0)
No regimen 4 (1) 0 (0)
Total number 293 101
Boost 10 2 5 267 (92) 94 (93)
9 3 3 8 (3) 3 (3)
16 2 8 6 (2) 3 (3)
4–15 2–3 2–7 8 (3) 1 (1)
No regimen 4 (1) 0 (0)
Total number 293 101
B. Hypofractionation
WB 40.05 2.67 15 5 (2) 3 (3)
40–43.2 2.5–2.7 16 111 (38) 41 (41)
42.5–50 2.5 17–20 9 (3) 1 (1)
No regimen 166 (57) 56 (56)
Total number 291 101
Boost 5–9 2.5–3 3 23 (7.9) 2 (2)
10–10.64 2.5–2.66 4 69 (23.7) 28 (28)
10–15 2–2.66 5–6 22 (7.6) 9 (9)
No regimen 177 (60.8) 62 (62)
Total number 291 101
Fr = fractionation; WB = whole breast.
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on the margin width [19]. Their meta-analysis showed that there
was a weak relationship between local recurrence, margin width and
dose in contemporary multimodality treatment, and concluded that
in patients with negative margins (no ink on the tumor), the use
and dose of BI should be based on an a priori estimation of local
recurrence risk in the ipsilateral converted breast, and should not be
determined, in isolation, by the width of the surgical margin.
According to their report, to estimate the a priori risk of local recur-
rence, not only margin width but also the other factors (age, sub-
type, the use of systemic therapies, etc.) should be taken into
account. This survey showed that some institutes regarded the other
factors (age, subtype, etc.) as determining factors for the selection
of BI, but (in 2016) many institutes seemed to put the emphasis on
margin width in selecting BI in Japan. In the future, the use of all of
the criteria related to the a priori risk of local recurrence is likely to
spread in Japan, with novel and future evidence for the benefits of
optimizing the balance between the benefit and burden of BI. The
changes in the Japanese trends in the criteria for selecting BI are
worthy topics for future studies.
In regard to age, 38% of Japanese institutes in this survey
regarded age as an important factor and 19% regarded it as the
dominant factor to use in selection of BI. Many institutes used the
age range of ≤40 or ≤50 years as the criterion for applying BI, as
young age is associated with local recurrence. The Oxford meta-
analysis of breast-conserving surgery demonstrated an inverse rela-
tionship between the rate of any first recurrence and age [1]. The
EORTC 22881–10882 trial showed that the relative benefit of BI
for local control was larger in younger patients than in older
patients, and the absolute risk reduction at 20 years was the largest
in patients ≤40 years of age (36.0% in the no boost group versus
24.4% in the boost group) [3]. Japanese institutes seemed to use
the age range of ≤40 or ≤50 years based on the above evidence.
A majority (85%) of the institutes included in the survey per-
formed bilateral post-BCS RT synchronously in patients with syn-
chronously diagnosed bilateral breast cancers, indicating the high
prevalence of this procedure in Japan. This survey also revealed that
most of the institutes (98%) did not perform APBI in clinical prac-
tice, and thus APBI may not be the method of choice for post-BCS
RT in Japan. One of the reasons for this is likely to be that the
Japanese Breast Cancer Society Clinical Practice Guideline for
Breast Cancer had recommended APBI should be performed in a
clinical trial [12] . It is also possible that this tendency may be due
to the variation in the outcomes of APBI in different studies and
the questionable superiority of APBI over WBI [20]. However,
APBI or PBI could be available for selected patients in the near
future, based on newly accumulating evidence [8, 21, 22]. Changes
in the Japanese trends regarding the use of APBI and PBI would be
worthy topics for future studies.
This survey has some limitations. First, this questionnaire was
not answered by all eligible institutes in Japan (institutions with ≥1
radiation oncologist working full-time and with ≥10 patients treated
with post-BCS RT annually), which implies that the results may not
be representative of clinical practices of post-BCS RT in Japan.
However, the majority of the SHs (which are the primary cancer
treatment centers in Japan) participated in this survey. Therefore,
we believe that this survey presents an accurate overview of the ten-
dencies in the clinical practice of post-BCS RT in 2016 in Japan.
Second, the respondents had to select the most appropriate answers
from several options in this questionnaire, which may have uninten-
tionally guided them. Third, this survey disclosed the landmarks of
field edges for treatment planning, although this information might
be insufficient for detecting precise differences in dose distributions
on the conserved breasts as applied by the different institutes.
Future investigations would need detailed digital imaging data to
better understand the variation in prevalent radiation therapy.
The findings of this nationwide survey provided an overview of
the current clinical practices of post-BCS RT in Japan and the
Fig. 3. Dose fractionation: conventional fractionation vs
hypofractionation. CF = conventional fractionation; HF =
hypofractionation. In this investigation, specialized hospitals
were defined as university hospitals or hospitals designated
for cancer treatment; the remaining hospitals were termed
‘general hospitals’.
Table 2. The list of important factors taken into
consideration in making the decision to deliver boost
irradiation, and the percentage of hospitals using this
approach






Surgical margin condition 97 94
Nodal metastasis 5 2
Lymphovascular invasion 8 0.3
Subtypes of breast cancer 6 2
Others 7 6
*A dominant factor is defined as a factor having a strong impact on the decision
to apply BI, i.e. the use of BI could be determined solely by the dominant factor.
BI = boost irradiation.
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results can be compared with those of future investigations into
Japanese practice of post-BCS RT. This study has provided not
only the features of current Japanese practice of post-BCS RT in
2016, but also topics for future studies.
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